ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc Stock Forecast & Price Prediction

Live ACADIA Pharmaceuticals Inc Stock (ACAD) Price
$18.62

15

Ratings

  • Buy 11
  • Hold 4
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$18.62

P/E Ratio

-46.30

Volume Traded Today

$2.1M

Dividend

Dividends not available for ACAD

52 Week High/low

33.99/14.55

ACADIA Pharmaceuticals Inc Market Cap

$2.88B

🛑 Alert: These ten stocks could have higher potential than $ACAD 🛑

Before you buy ACAD you’ll want to see this list of ten stocks that have huge potential. Want to see if ACAD made the cut? Enter your email below

ACAD Summary

Based on ratings from 15 stock analysts, the ACADIA Pharmaceuticals Inc stock price is expected to increase by 48.23% in 12 months. This is calculated by using the average 12-month stock price forecast for ACADIA Pharmaceuticals Inc. The lowest target is $17.00 and the highest is $39.00. Please note analyst price targets are not guaranteed and could be missed completely.

ACAD Analyst Ratings

ACAD is a stock in Health Care which has been forecasted to be worth $27.60 as an average. On the higher end, the forecast price is $39.00 USD by jason butler from JMP Securities and on the lower end ACAD is forecasted to be $17.00 by jay olson from Oppenheimer.

ACAD stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

evan seigerman
BMO Capital

Buy

$31.0

initiatedcoverage

Jun 26, 2024
keith tapper cfa
BMO Capital

Buy

$31.0

initiatedcoverage

Jun 26, 2024
gregory renza
RBC Capital

Buy

$29.0

maintained

Jun 25, 2024
jay olson
Oppenheimer

Hold

$17.0

maintained

May 10, 2024
paul matteis
Stifel Nicolaus

Hold

$21.0

maintained

May 10, 2024
ami fadia
Needham

Buy

$30.0

maintained

May 9, 2024
tazeen ahmad
Bank of America Securities

Hold

$22.0

reiterated

May 9, 2024
jason butler
JMP Securities

Buy

$39.0

reiterated

May 9, 2024
andrew fein
H.C. Wainwright

Buy

$27.0

maintained

May 9, 2024
sumant kulkarni
Canaccord Genuity

Buy

$33.0

maintained

May 9, 2024
marc goodman
Leerink Partners

Buy

$28.0

maintained

May 8, 2024
uy ear
Mizuho Securities

Hold

$21.0

maintained

May 8, 2024
joel beatty
Robert W. Baird

Buy

$28.0

rated

May 8, 2024
david hoang
Citi

Buy

$30.0

maintained

May 8, 2024
ashwani verma
UBS

Buy

$27.0

maintained

Apr 30, 2024
tessa romero
J.P. Morgan

Buy

$25.0

maintained

Mar 25, 2024
jeffrey hung
Morgan Stanley

Buy

$30.0

maintained

Mar 13, 2024
charles duncan
Cantor Fitzgerald

Buy

$37.0

maintained

Mar 12, 2024
ritu baral
TD Cowen

Buy

$35.0

maintained

Mar 7, 2024
neena bitritto garg
Deutsche Bank

Hold

$24.0

maintained

Feb 28, 2024

ACAD Company Information

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACAD
ACADIA Pharmaceuticals Inc (ACAD)

When did it IPO

2004

Staff Count

610

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Stephen R. Davis J.D.

Market Cap

$2.88B

ACADIA Pharmaceuticals Inc (ACAD) Financial Data

In 2023, ACAD generated $726.4M in revenue, which was a increase of 40.45% from the previous year. This can be seen as a signal that ACAD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$441.8M

Revenue From 2021

$484.1M

9.60 %
From Previous Year

Revenue From 2022

$517.2M

6.83 %
From Previous Year

Revenue From 2023

$726.4M

40.45 %
From Previous Year
  • Revenue TTM $813.8M
  • Operating Margin TTM 7.4%
  • Gross profit TTM $684.8M
  • Return on assets TTM -0.4%
  • Return on equity TTM -0.4%
  • Profit Margin -0.2%
  • Book Value Per Share 2.81%
  • Market capitalisation $2.88B
  • Revenue for 2021 $484.1M
  • Revenue for 2022 $517.2M
  • Revenue for 2023 $726.4M
  • EPS this year (TTM) $-0.37
... ...

Similar Stocks to ACADIA Pharmaceuticals Inc - ACAD

🛑 Alert: These ten stocks could have higher potential than $ACAD 🛑

Before you buy ACAD you’ll want to see this list of ten stocks that have huge potential. Want to see if ACAD made the cut? Enter your email below

...

ACAD Frequently asked questions

The highest forecasted price for ACAD is $39.00 from jason butler at JMP Securities.

The lowest forecasted price for ACAD is $17.00 from jay olson from Oppenheimer

The ACAD analyst ratings consensus are 11 buy ratings, 4 hold ratings, and 0 sell ratings.